SciSparc, Clearmind Medicine file Israeli patent application for depression

SciSparc (SPRC) announced that NeuroThera Labs, a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine (CMND) by filing an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, targeting depression. The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine. This therapy targets depression treatment using the combination of MEAI and PEA. This new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed through the collaboration, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression.